ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2014

Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Angeles Alvarez Secord et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.